Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Fatigue 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × auricularum × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡